Kalamazoo, Michigan - Stryker officials announce the global launch of the new medical device, the Trevo XP ProVue Retriever. The Trevo XP ProVue Retriever expands the ProVue Retriever line with additional size and shape options for physicians. The Trevo ProVue Retrievers are the world's first stent retrievers with full-length visibility and are built on Trevo technology, which has delivered strong clinical results and positive patient outcomes for acute ischemic stroke patients.
"The Trevo XP ProVue Retriever provides some of the best performance of the devices I've used over the years to treat acute ischemic stroke. The unique full-length visibility provides key information that we can use to successfully remove clots more efficiently. When combined with the Merci Balloon Guide Catheter, I feel I have a system that is easy to use and provides the potential for consistently good results," said Ronald Budzik, M.D., interventional neuroradiology/neurointerventional surgery; chair, neuroscience clinical operations council; co-director, Riverside Comprehensive Stroke Center, OhioHealth, Riverside Methodist Hospital, Columbus, Ohio.
Joey D. English, M.D., Ph.D., director of Neurointerventional Services, California Pacific Medical Center, San Francisco, Calif., added, "The new Trevo XP ProVue Retriever is smooth and easy to use. It has excellent deliverability and the visibility it provides allows me to confidently deploy the device in the best position to capture and remove the clot. I can visualize the clot and strut interaction during the case and this provides valuable feedback for clot removal."
"The Trevo XP ProVue Retriever is an example of the passion the Stryker Neurovascular team has towards innovating technology that assists physicians in treating their patients who are suffering from Acute Ischemic Stroke," said Mark Paul, president of Stryker's Neurovascular division. "We set a new standard in stent retriever technology with the launch of the first Trevo ProVue Retriever. This second generation device expands the ProVue line and demonstrates our ongoing dedication to providing physicians with the most advanced tools available."
The Trevo XP ProVue Retriever is supported by robust clinical evidence from the TREVO and TREVO 2 clinical trials, which demonstrated high revascularization and a high rate of good clinical outcomes compared to the earlier generation Merci Retriever. Additionally, physicians participating in the Trevo Retriever Registry, a multi-center, international data collection study, will be collecting real world data on the Trevo XP ProVue Retriever. The device has been granted 510(k) market clearance by the U.S. Food and Drug Administration and is also available in international markets where it has been cleared for sale.
View an animation of the Trevo XP ProVue Retriever here.